Supernus jumps after hours on Q3 earnings beat, raises guidance

• Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 results:
• Revenue $155.14M (+51.9% Y/Y), includes net product sales of $152.1M and royalty revenues of $3M, beats consensus by $24.38M.
• Operating earnings of $56.1M, compared to $39.7M last year.
• Net earnings of $40M, or EPS of $0.74, compared to $28.9M, or $0.54 prior.
• R&D expenses remain unchanged.
• FY guidance raised: Net product sales $500M-525M, and operating earnings $145M-160M.
• On track to initiate commercial launch of SPN-812 in January 2021, if approved by the FDA.
• The Company expects to launch SPN-830 in Q4 of 2021, if approved by the FDA.
• https://seekingalpha.com/news/3630841-supernus-pharmaceuticals-stock-scales-19-during-after-hours-on-q3-earnings-beat-raises